February 26, 2024Amsterdam, the Netherlands – argenx ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March: TD Cowen 44th Annual Health Care Conference. Fireside chat on Monday, March 4, 2024 at 11:10 a.m. ET in Boston, MA.Leerink Global Biopharma Conference. Fireside chat on Monday, March 11, 2024 at 2 ...

Core Insights - argenx is a global immunology company focused on improving the lives of individuals with severe autoimmune diseases [2] - The company is participating in several investor conferences in March 2024, including the TD Cowen 44th Annual Health Care Conference, the Leerink Global Biopharma Conference, and the Barclays Global Healthcare Conference [1] Company Overview - argenx partners with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [2] - The company has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in multiple regions including the U.S., Japan, Israel, the EU, the UK, Canada, and China [2] - argenx is evaluating its drug efgartigimod in various serious autoimmune diseases and advancing several earlier-stage experimental medicines within its therapeutic franchises [2]

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [2] - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [2] - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in multiple regions including the U.S., Japan, Israel, the EU, the UK, Canada, and China [2] Upcoming Events - argenx will host a conference call and audio webcast on February 29, 2024, at 2:30 PM CET (8:30 AM ET) to discuss its full year 2023 financial results and provide a fourth quarter business update [1] - The live call can be accessed on the Investors section of the argenx website, with a replay available for approximately one year following the presentation [1] Product Development - The company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises [2]

Core Viewpoint - The Federal Reserve's potential interest rate cuts may lead to increased investment in riskier sectors, particularly in biotech, which is often speculative due to its reliance on trial results and regulatory approvals [1]. Company Summaries Xenon Pharmaceuticals (XENE) - Xenon Pharmaceuticals is focused on developing neurological therapies, particularly for major depressive disorders, with a key milestone being the XEN1101 Phase 3 Program [2]. - Analysts project a significant earnings per share (EPS) growth of 107.8% over the next 12 months [2]. - The forward price-to-earnings (P/E) ratio is extremely high at 538.0, indicating strong market expectations for future earnings [3]. Argenx (ARGX) - Argenx has a robust product pipeline with over a dozen projects moving towards registration, particularly in autoimmune diseases [5]. - The ARGX-118 project, currently in Phase One, aims to prevent airway inflammation, a growing concern post-COVID-19 [5]. - The stock's forward P/E is 111.7, supported by projected EPS growth of approximately 240.0% in the coming year [6]. IntraCellular Therapies (ITCI) - IntraCellular Therapies focuses on neurological disorders, including bipolar depression and Parkinson's disease, primarily in the U.S. market [7]. - The company has the lowest forward P/E among the three at 88.8, but still shows strong potential for growth [7]. - Analysts anticipate an impressive EPS growth of 225.8% this year, driven by the Lumateperone pipeline nearing the end of Phase 3 trials [8].

Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics ...

Key PointsThe healthcare sector is quickly heating up in all the fundamental ways professional traders seek. Within it, you can spot five stocks calling for new moves to the upside, backed by similar tailwinds.Analysts see the same factors at play and boldly project triple-digit EPS growth in all of them.5 stocks we like better than Axsome TherapeuticsWhile most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their ...

Christoph Burgstedt Shares of argenx (NASDAQ:ARGX) have somewhat recovered from the negative reaction to the second late-stage clinical failure of Vyvgart in a row - phase 3 trial in immune thrombocytopenia ('ITP') and phase 3 trial in pemphigus vulgaris ('PV'). The recovery was probably driven by several factors - bargain hunters and the overall positive industry sentiment since early November and the company providing a bullish commercial and pipeline update ahead of and at the JPMorgan Healthcare Confere ...

Availability of VYVGART® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) injectio ...

One stock that might be an intriguing choice for investors right now is argenx SE (ARGX) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the ...

Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024 Reported positive data from Phase 2 ARDA study establishing proof-of-concept for empasiprubart in MMN Data from six Phase 2 proof-of-concept trials expected by end of 2024 Nominated four new pipeline candidates with IND filings expected by end of 2025 January 8, 2024, 7:00 AM CET Amsterdam, the Netherlands ...